Our findings in total suggest that inhibition of SHP2 could have clinical utility in HNSCC, sensitive HNSCCs can be identified by expression levels of EREG, and SHP2 inhibition leads to downregulation of both MEK and PI3K pathways in sensitive HNSCCs. This evidence concerns the gene MAP2K7 and head and neck squamous cell carcinoma.